Lipoxygenase inhibitors
AssigneeSRI International
InventorsLing Jong, Nathan Collins, Raymond Ng
Life of this patent
Estimating the term…
Abstract
Various embodiments of the present disclosure are directed to compounds having Formula I, Formula II, Formula IIA, Formula III, Formula IIIA, Formula IIIB, and/or pharmaceutically acceptable salts thereof. The compounds can be suitable for inhibiting lipoxygenases and/or treating associated diseases. In some embodiments, subject compounds are used to prepare a composition that is effective in treating neurodegenerative diseases.
Claims36
A compound having Formula I:
- wherein:
- n is 0-2, such that when n=0, there is a direct bond between B and the NH group and with no R3, and when n=1 or 2, the carbons in these bonds are optionally substituted with one R3 group;
- A is a 6 membered heteroaryl or a 6 membered aryl, wherein the 6 membered heteroaryl or 6 membered aryl is further independently substituted with one to three R1 groups;
- B is a 5-6-membered heterocycle, a 5-6 membered aryl, or a 5-6 membered cyclohexyl, wherein the 5-6 membered heterocycle, 5-6 membered aryl, or 5-6 membered cyclohexyl is unsubstituted or independently substituted with up to three R2 groups;
- each X1, X2, X3, X4, X5, and X6 independently comprising:
- C, N, or O;
- each R1 independently comprising:
- halo, C1-4 alkyl, —NRxRy, —O(CH2)2Rx, —O(CH2)2NRxRy, —NHC(O)—C2-4 alkyl, —(CH2)3NRxRy, —NH(CH2)2RxRy, —NHCH2CRxRyRz, a 5-6 membered aryl, a 5-10 membered heterocycle, a 5-10 membered heteroaryl, or a 5-10 membered heterocyclic aryl,
- wherein the one to three R1 groups are optionally further substituted with Ra and/or Rb,
- wherein two R1 groups optionally come together to form a 5-6 membered heteroaryl, [5-6 membered heterocycle, 5-6 membered cycloalkyl, 5-6 membered aryl], wherein the 5-6 membered heteroaryl, [5-6 membered heterocycle, 5-6 membered cycloalkyl, 5-6 membered aryl] is optionally further substituted with one to three Ra groups;
- each R2 independently comprising:
- halo, C1-2 methoxy, or —C(O)ORx;
- wherein two R2 groups on adjacent atoms optionally come together to from a 5-6 membered aryl, wherein the 5-6 membered aryl is optionally further substituted with one to three Ra groups;
- R3 comprising:
- C1-3 haloalkyl, or oxo;
- Rx, Ry, and Rz each independently comprising:
- H, halo, C1-2 alkyl, C1-2 alcohol, C1-2 alkoxy, C1-2 haloalky, or —NRaRb, wherein any two of Rx, Ry, or Rz optionally come together to form a 4-6 membered heterocycle, 5-6 membered aryl, wherein Rx, Ry, and Rz are each optionally further substituted with Ra and Rb;
- Ra and Rb each independently comprising:
- H, halo, cyano, oxo, C1-3 alkyl, —C(O)OR′, C1-3 haloalkyl, 5-6 membered aryl, 5-6 membered heteroaryl, or 4-6 membered heterocycle,
- wherein Ra and Rb are each optionally further substituted with R′;
- R′ is C1-3 alkyl, C1-3 haloalkyl, or C5-6 membered heteroaryl;
- and
- a pharmaceutically acceptable salt thereof.
A compound having Formula II,
- wherein:
- A is a 6 membered heteroaryl or a 6 membered aryl, wherein the 6 membered heteroaryl or 6 membered aryl is independently substituted with one to three R1 groups;
- B is a 6 membered heterocycle, a 6 membered aryl, or a 6 membered cyclohexyl, wherein the 6 membered heterocycle, 6 membered aryl, or 6 membered cyclohexyl is either unsubstituted or independently substituted with up to two R2 groups;
- each X1, X2, X3, and X4 independently comprising:
- C, N, or O;
- each R1 independently comprising:
- halo, C1-4 alkyl, —NRxRy, —O(CH2)2RxRy, —O(CH2)2NRxRy, —NHC(O)-alkyl(2-4), —(CH2)3NRxRy, —NH(CH2)2RxRy, —NHCH2CRxRyRz, a 5-6 membered aryl, a 5-10 membered heterocycle, a 5-10 membered heteroaryl, or a 5-10 membered heterocyclic aryl,
- wherein two R1 groups optionally come together to form a 5-6 membered heteroaryl, [5-6 membered heterocycle, 5-6 membered cycloalkyl, 5-6 membered aryl], wherein the 5-6 membered heteroaryl, [5-6 membered heterocycle, 5-6 membered cycloalkyl, 5-6 membered aryl] is optionally further substituted with one to three Ra groups,
- wherein each of the one to three R1 groups are optionally independently further substituted with Ra or Rb;
- each R2 independently comprising halo, C1-2 methoxy, or —C(O)ORx;
- each Rx, Ry, and Rz independently comprising:
- H, halo, C1-2 alkyl, C1-2 alcohol, C1-2 alkoxy, C1-2 haloalkyl, or —NRaRb,
- wherein two of Rx, Ry, or Rz optionally come together to form a 4-6 membered heterocycle, 5-6 membered aryl, wherein each of the Rx, Ry, and Rz are optionally further substituted with Ra and Rb;
- Ra and Rb each independently comprising:
- H, halo, cyano, oxo, C1-3 alkyl, —C(O)OR′, C1-3 haloalkyl, a 5-6 membered aryl, a 5-6 membered heteroaryl, or a 4-6 membered heterocycle,
- wherein Ra and Rb are optionally and independently further substituted with R′;
- R′ is C1-3 alkyl, C1-3 haloalkyl, or a 5-6 membered heteroaryl;
- and
- a pharmaceutically acceptable salt thereof.
A compound having Formula IIA:
- wherein:
- B is cyclohexyl, a 6-membered heterocycle, a 6-membered aryl, or a 6-membered heteroaryl;
- X1, X3, and X4 are each independently C, N, or O;
- R1 is —C1-3 alkyl-Rx, —(CH2)2NRxRy, —CH2C(RxRy)Ra, —CH2C(RxRy)NRaRb, or a 5-6 membered aryl, wherein R1 is optionally further substituted with Ra or Rb;
- R2 is H, halo, C1-3 alkyl, C1-3 haloalkyl, or C1-3 haloalkoxy,
- wherein R1 and R2 optionally come together to form a 5-6 membered heterocycle, wherein the 5-6 membered heterocycle is optionally further substituted with Ra, Rb, or both Ra and Rb;
- R3 is H or halo;
- R4 is halo, or C1-3 alkyl;
- Rx and Ry are each independently a C5-6 membered heterocycle,
- Ra and Rb are each independently C1-3 alkyl or C1-3 haloalkyl,
- wherein Ra and Rb are optionally further substituted with a R′ group;
- R′ group is a 5 membered heteroaryl or a 5-6 membered heterocycle;
- and
- pharmaceutically acceptable salts thereof.
A compound having Formula IIB:
- wherein:
- B is cyclohexyl, a 6 membered heterocycle, a 6 membered aryl, or a 6 membered heteroaryl;
- each X is independently C, N, or O;
- R1 is H, C1-3 alkyl, a 5-6 membered heterocycle, a 5-6 membered aryl, a 5-6 membered heteroaryl, a 5-10 membered cycloheteroaryl, a 5-10 membered heteroaryl, or —C(O)Rx;
- R2a and R2b are each independently:
- H, C1-3 alkyl, a 5-6 membered aryl, —NRx(CH2)2Ry, —NRx(CH2)3Ry, —NRxC(O)(CH2)2Ry, —NH(CH2)2NRxRy, —O(CH2)2Rx, —NH(CH2)CRxRyCH2Ra, —NH(CH2)CRxRyCH2NRaRb, —(CH2)3NRxRy, a 5-10 membered cycloheteroaryl, or —NRxRy;
- R′2 is H or a halo;
- each R3 is independently H, halo, C1-3 alkyl, —O(CH2)2NRxRy, —NRx(CH2)2Ry, —NRxRy, or —(CH2)3NRxRy;
- R4 is halo;
- further wherein R1 with either R2a or R2b optionally come together to form a 5-6 membered heterocycle, the 5-6 membered heterocycle is optionally further substituted with one or more of Ra and Rb, and
- wherein R1, R2a, R2b, R′2, and R3 are each optionally and independently substituted with one or more Ra;
- Rx and Ry are each independently H, C1-4 alkyl, 5-6 membered aryl, 5-6 membered heteroaryl, —NRaRb,
- wherein Rx and Ry each optionally come together to form 4-5 membered heterocycle, and
- wherein Rx or Ry optionally and independently are further substituted with Ra and/or Rb;
- Ra and Rb are each independently H, halo, oxo, cyano, C1-3 alkyl, C1-3 alcohol, C1-3 alkoxy, phenyl, —(CH2)2R′, 5-6 membered heteroaryl, or 5-6 membered heterocycle;
- R′ is a 5 membered heteroaryl;
- and
- pharmaceutically acceptable salts thereof.
A compound having Formula III:
- wherein:
- n is 1-2;
- B is a cyclohexyl, a 6-membered heterocycle, a 6-membered aryl, or a 6-membered heteroaryl;
- X1, X2, X3, X4, and X5 are each independently C, N, or O;
- R1 is halo, C1-4 alkyl, —NRxRy, —O(CH2)2NRxRy, a 6 membered cyclohexyl, a 6 membered heterocycle, a 6 membered aryl, a 6 membered heteroaryl, or a 5-10 membered cycloalkyl,
- wherein when there are two R1 groups, the two R1 groups optionally come together to form a 6 membered heteroaryl;
- wherein each R1 is optionally and independently further substituted with one or more Ra;
- each R2 is halo or C1-3 alkoxy;
- each R3 is independently H, oxo, C1-3 haloalkyl, or a hydroxyalkyl,
- wherein when one or more R3 is hydroxyalkyl, the one or more of R3 optionally comes together with a C of Formula III to form a 4 membered heterocycle;
- Rx and Ry are each independently H, C1-3 alkyl, a 6 membered aryl, or a 6 membered heteroaryl,
- wherein Rx and Ry are each optionally and independently further substituted with one or more Ra;
- Ra is halo, oxo, cyano, C1-3 haloalkyl, —NR′R′, a 5-6 membered aryl, a 5-6 membered heteroaryl, or a 5-6 membered heterocycle, and
- wherein the one or more Ra optionally come together to form a 4-5 membered heterocycle;
- R′ is C1-3 alkyl;
- and
- pharmaceutically acceptable salts thereof.
A compound having Formula IIIA:
- wherein:
- n is 1-2;
- B is a cyclohexyl, a 6-membered heterocycle, a 6-membered aryl, or a 6-membered heteroaryl;
- X1, X2, and X3 are each independently C, N, or O;
- R1 is C1-3 alkyl,
- wherein R1 is optionally substituted with one or more Ra or Rb;
- R2 is H, halo, C1-3 haloalkyl, C1-4 alkyl, 5-6 membered aryl, 5-6 membered cycloalkyl, 5-6 membered heterocycle, 5-10 membered heteroaryl, 5-10 membered cycloaryl;
- R3 is H or halo;
- each R4 is independently H, oxo, a C1-3 haloalkyl, or a hydroxyalkyl,
- wherein when one or more of R4 is hydroxyalkyl, the one or more R4 optionally comes together with a C of the Formula IIIA to form a 4 membered heterocycle;
- R5 is halo, or a 4-5 membered heterocycle;
- R1, R2, R4, and R5 are each optionally and independently be substituted with up to two Ra or Rb;
- Ra and Rb are each independently C1-3 alkyl, C1-3 haloalkyl, 5-6 membered heterocycle, 5-6 membered heteroaryl, —N/—NR′R′,
- wherein an Ra and Rb optionally come together to form a 4-5 membered heterocycle,
- wherein Ra and Rb are each optionally and independently further substituted with one or more R′ groups;
- R′ is halo or C1-3 alkyl;
- and
- pharmaceutically acceptable salts thereof.
A compound having Formula IIIB:
- wherein:
- n is 1-2;
- B is a cyclohexyl, a 6-membered heterocycle, a 6-membered aryl, or a 6-membered heteroaryl;
- X1, X2, X3 and X4 are each independently C or N;
- R1 is H, a C1-3 alkyl, or a 5-6 membered aryl;
- wherein R1 is optionally substituted with one or more Ra or Rb;
- R2a and R2b are each independently C1-4 alkyl, or a 5-6 membered heteroaryl;
- R1 and R2a, or R2b optionally come together to form a 5-6 membered aryl or 5-6 membered heteroaryl, the optional 5-6 membered aryl or 5-6 membered heteroaryl being optionally further substituted with Ra and Rb;
- R3 is H, halo, or C1-3 alkoxy;
- each R4 is independently H or oxo;
- R5 is halo or a 4-5 membered heterocycle;
- R1, R2a, R2b, R3, and R5 are each independently and optionally further substituted with Ra and Rb;
- Ra and Rb are each independently H, halo, oxo, cyano, or a C1-3 alkyl, 5-6 membered heteroaryl;
- and
- pharmaceutically acceptable salts thereof.
Dependencies are inferred from the claim text.